[144] Arcutis Biotherapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) Form 144 reports a proposed sale of 504 common shares by a person for whose account the securities are to be sold, with an aggregate market value of $8,829 and an approximate sale date of 09/09/2025 on NASDAQ. The filing states these 504 shares were acquired on 05/01/2025 upon restricted stock vesting from Arcutis Biotherapeutics.

The filing also discloses prior sales by the same person in the past three months: 11,547 shares on 08/04/2025 for $165,429 and 9,625 shares on 09/08/2025 for $168,800. The filer certifies no undisclosed material adverse information and includes the standard attestation language required by Rule 144.

Insights

Securities Analyst

TL;DR: Insider reported small planned sale of vested restricted shares following recent sales.

The Form 144 documents a planned disposal of 504 vested restricted shares valued at $8,829, and shows recent insider sales totaling 21,172 shares across August and September 2025 for gross proceeds of $334,229. For investors, these are clear, contemporaneous disclosures of insider selling activity required under Rule 144. The filing does not present any company operational or financial metrics, nor does it state any trading plan date indicating Rule 10b5-1 reliance. Impact depends on investor interpretation of insider liquidity needs rather than new company information.

Corporate Governance Expert

TL;DR: Disclosure complies with Rule 144; no material adverse facts are claimed.

The filing identifies the nature of acquisition as restricted stock vest and provides required details on prior sales, satisfying Form 144 content requirements. The signer attests to lack of undisclosed material adverse information. There is no indication in the filing of a 10b5-1 trading-plan adoption date, which means market participants cannot infer preplanned trading protection from insider liability. Governance implications are procedural disclosure rather than substantive corporate change.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill 8890 Lyra Dr th Flr Columbus OH 43240	504	8829.00	119905078	09/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2025	Restricted stock vest	Arcutis Biotherapeutics			504	05/01/2025	na

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Todd Franklin Watanabe 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	common	08/04/2025	11547	165429.00
Todd Franklin Watanabe 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	09/08/2025	9625	168800.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ARQT Form 144 report say about the planned sale on 09/09/2025?

It reports a proposed sale of 504 common shares valued at $8,829, expected to occur on 09/09/2025 on NASDAQ.

How were the 504 shares acquired according to the filing?

The 504 shares were acquired on 05/01/2025 through a restricted stock vest from Arcutis Biotherapeutics.

What insider sales in the past three months does the Form 144 disclose for ARQT?

It discloses sales of 11,547 shares on 08/04/2025 for $165,429 and 9,625 shares on 09/08/2025 for $168,800.

Does the filing state reliance on a Rule 10b5-1 trading plan?

The filing shows a field for plan adoption or instruction date but does not provide a date indicating reliance on a Rule 10b5-1 plan.

Does the filer attest to knowledge of any undisclosed material adverse information?

Yes. By signing, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.